Mostrar el registro sencillo del ítem

Inhibition of T-cell activity in alopecia areata: recent developments and new directions

dc.rights.licenseopenen_US
dc.contributor.authorPASSERON, T.
dc.contributor.authorKING, B.
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorSENESCHAL, Julien
dc.contributor.authorSTEINHOFF, M.
dc.contributor.authorJABBARI, A.
dc.contributor.authorOHYAMA, M.
dc.contributor.authorTOBIN, D.J.
dc.contributor.authorRANDHAWA, S.
dc.contributor.authorWINKLER, A.
dc.contributor.authorTELLIEZ, J.-B.
dc.contributor.authorMARTIN, D.
dc.contributor.authorLEJEUNE, A.
dc.date.accessioned2024-09-25T14:37:49Z
dc.date.available2024-09-25T14:37:49Z
dc.date.issued2023
dc.identifier.issn1664-3224en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/201809
dc.description.abstractEnAlopecia areata (AA) is an autoimmune disease that has a complex underlying immunopathogenesis characterized by nonscarring hair loss ranging from small bald patches to complete loss of scalp, face, and/or body hair. Although the etiopathogenesis of AA has not yet been fully characterized, immune privilege collapse at the hair follicle (HF) followed by T-cell receptor recognition of exposed HF autoantigens by autoreactive cytotoxic CD8+ T cells is now understood to play a central role. Few treatment options are available, with the Janus kinase (JAK) 1/2 inhibitor baricitinib (2022) and the selective JAK3/tyrosine kinase expressed in hepatocellular carcinoma (TEC) inhibitor ritlecitinib (2023) being the only US Food and Drug Administration–approved systemic medications thus far for severe AA. Several other treatments are used off-label with limited efficacy and/or suboptimal safety and tolerability. With an increased understanding of the T-cell–mediated autoimmune and inflammatory pathogenesis of AA, additional therapeutic pathways beyond JAK inhibition are currently under investigation for the development of AA therapies. This narrative review presents a detailed overview about the role of T cells and T-cell–signaling pathways in the pathogenesis of AA, with a focus on those pathways targeted by drugs in clinical development for the treatment of AA. A detailed summary of new drugs targeting these pathways with expert commentary on future directions for AA drug development and the importance of targeting multiple T-cell–signaling pathways is also provided in this review.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enAlopecia areata
dc.subject.enAutoimmune disease
dc.subject.enT cells
dc.subject.enT-cell receptor
dc.subject.enJAK inhibitor
dc.title.enInhibition of T-cell activity in alopecia areata: recent developments and new directions
dc.typeArticle de revueen_US
dc.identifier.doi10.3389/fimmu.2023.1243556en_US
dc.subject.halSciences du Vivant [q-bio]/Immunologieen_US
dc.identifier.pubmed38022501en_US
bordeaux.journalFrontiers in immunologyen_US
bordeaux.volume14en_US
bordeaux.hal.laboratoriesImmunoConcEpT - UMR 5164en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04709552
hal.version1
hal.date.transferred2024-09-25T14:37:53Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccCC BYen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers%20in%20immunology&rft.date=2023&rft.volume=14&rft.eissn=1664-3224&rft.issn=1664-3224&rft.au=PASSERON,%20T.&KING,%20B.&SENESCHAL,%20Julien&STEINHOFF,%20M.&JABBARI,%20A.&rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
ImmuniConcept_FrontImmunol_202 ...
Tamaño:
2.177Mb
Formato:
PDF
Ver/Abrir
Thumbnail
Nombre:
license_rdf
Tamaño:
914bytes
Formato:
application/rdf+xml
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem